Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
A Almirall SA
A
Open
SectorHealthcare
9.63 1.8
Overview
Share price change
24h
Min
9.43
Max
9.65
Income | -430K -2.1M |
|---|---|
Sales | 28M 258M |
P/E Sector Avg | 187.4 57.333 |
EPS | 0.04 |
Dividend yield | 1.96 |
Profit margin | -0.814 |
Employees | 2,026 |
EBITDA | 3.9M 45M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +46.66% upside |
Dividend yield Sector Avg | 1.96% 2.63% |
|---|---|
Next Earnings | 12 May 2025 |
Market Cap | -26M 2B |
|---|---|
Previous open | 7.83 |
Previous close | 9.63 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Almirall SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Almirall SA Forecast
Price Target
By TipRanks
46.66% upside
12 Months Forecast
Average 13.83 EUR 46.66%
High 17 EUR
Low 12 EUR
Based on 3 Wall Street analysts offering 12 month price targets forAlmirall SA - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
